Teva, Mylan Drop on Announcement of Epinephrine Injector Rival | Ctech
FDA Approves Teva's Generic EpiPen As Stock Rises
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
Mylan vs Teva Pharmaceuticals | Comparably
Teva Launches Site for Generic EpiPen Equivalent | SnackSafely.com
Teva Offers to Buy Mylan for $40 Billion - WSJ
Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
Teva Pharmaceutical Gains Approval For Generic EpiPen, Mylan Shares Flat
How Mylan tried to keep Teva from selling a generic EpiPen
Teva makes $40 billion offer for Mylan
Teva scrambles to match 30% Copaxone discounts from Mylan's knockoff: analyst | Fierce Pharma
Mylan Teva EpiPen Generic Auto-Injector Market
Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan - TheStreet
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Teva makes $40.1 billion takeover bid for Mylan | Mint
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Lawmakers accuse drugmakers Mylan, Teva of 'coordinated obstruction'
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
